Bioage Labs Inc is a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases by targeting the biology of human aging... Show more
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| AVLV | 93.03 | 0.17 | +0.18% |
| Avantis U.S. Large Cap Value ETF (AVLV) | |||
| BFOR | 23.51 | N/A | N/A |
| ALPS Barron's 400 ETF (BFOR) | |||
| FPAS | 23.80 | N/A | N/A |
| FPA Short Duration Government ETF (FPAS) | |||
| PNOV | 46.20 | -0.01 | -0.02% |
| Innovator U.S. Equity Power Buffer ETF - November (PNOV) | |||
| PCM | 4.94 | -0.08 | -1.59% |
| PCM Fund | |||
A.I.dvisor indicates that over the last year, BIOA has been loosely correlated with UPC. These tickers have moved in lockstep 43% of the time. This A.I.-generated data suggests there is some statistical probability that if BIOA jumps, then UPC could also see price increases.
| Ticker / NAME | Correlation To BIOA | 1D Price Change % | ||
|---|---|---|---|---|
| BIOA | 100% | -6.23% | ||
| UPC - BIOA | 43% Loosely correlated | +3.39% | ||
| NBIX - BIOA | 37% Loosely correlated | -4.41% | ||
| TKNO - BIOA | 26% Poorly correlated | -5.52% | ||
| HROW - BIOA | 23% Poorly correlated | -2.99% | ||
| TEVA - BIOA | 23% Poorly correlated | +0.19% | ||
More | ||||
| Ticker / NAME | Correlation To BIOA | 1D Price Change % |
|---|---|---|
| BIOA | 100% | -6.23% |
| Pharmaceuticals: Generic industry (83 stocks) | 3% Poorly correlated | -2.79% |
a producer of sustainable chemicals
Industry PharmaceuticalsGeneric
The Aroon Indicator for BIOA entered a downward trend on October 13, 2026. Tickeron's A.I.dvisor identified a pattern where the AroonDown red line was above 70 while the AroonUp green line was below 30 for three straight days. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options. A.I.dvisor looked at 67 similar instances where the Aroon Indicator formed such a pattern. In 59 of the 67 cases the stock moved lower. This puts the odds of a downward move at 88%.
The Momentum Indicator moved below the 0 level on September 09, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on BIOA as a result. In 31 of 39 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 79%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where BIOA declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 81%.
The RSI Indicator shows that the ticker has stayed in the oversold zone for 13 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an Uptrend is expected.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 14 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +4.96% 3-day Advance, the price is estimated to grow further. Considering data from situations where BIOA advanced for three days, in 98 of 119 cases, the price rose further within the following month. The odds of a continued upward trend are 82%.
BIOA may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Tickeron PE Growth Rating for this company is 6 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 32 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.879) is normal, around the industry mean (43.873). P/E Ratio (1.369) is within average values for comparable stocks, (141.710). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.152). Dividend Yield (0.000) settles around the average of (0.005) among similar stocks. P/S Ratio (29.762) is also within normal values, averaging (178.797).
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Price Growth Rating for this company is 66 (best 1 - 100 worst), indicating fairly steady price growth. BIOA’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 96 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 97 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. BIOA’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 84, placing this stock worse than average.